Hillsdale Investment Management’s Myriad Genetics MYGN Stock Holding History

Hillsdale Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-166,300	Closed	-$2.28M	–	664
2024 Q4	$2.28M	Buy	166,300 +13,120	+9%	+$242K	0.12%	208
2024 Q3	$4.2M	Buy	153,180 +2,000	+1%	+$54.1K	0.32%	101
2024 Q2	$3.7M	Buy	+151,180	New	+$3.32M	0.29%	126
2022 Q2	–	Sell	-27,000	Closed	-$680K	–	590
2022 Q1	$680K	Sell	27,000 -3,000	-10%	-$76.8K	0.04%	311
2021 Q4	$828K	Sell	30,000 -8,000	-21%	-$232K	0.06%	281
2021 Q3	$1.23M	Sell	38,000 -2,000	-5%	-$66.4K	0.09%	182
2021 Q2	$1.22M	Buy	+40,000	New	+$1.16M	0.1%	191
2013 Q4	–	Sell	-300	Closed	-$7K	–	567
2013 Q3	$7K	Hold	300	–	–	﹤0.01%	489
2013 Q2	$8K	Buy	+300	New	+$8.7K	﹤0.01%	475

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hillsdale Investment Management's MYGN Position: Q1 2025 in Review

Hillsdale Investment Management sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 166,300 shares — an estimated $2.28M sold.

Hillsdale Investment Management first reported a position in MYGN in Q2 2013 and held it in 9 quarters. The position peaked at $4.2M in Q3 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

Hillsdale Investment Management reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
Hillsdale Investment Management sold 166,300 Myriad Genetics shares in Q1 2025, an estimated $2.28M.
Hillsdale Investment Management first reported a position in Myriad Genetics in Q2 2013 and held it in 9 quarters.
Hillsdale Investment Management's Myriad Genetics position peaked at $4.2M in Q3 2024.
228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Hillsdale Investment Management's 13F filing for Q1 2025, filed 9 May 2025.